Compared with other ablative therapies, stereotactic body radiotherapy might offer a ‘particularly advantageous option’ for ...

Renal cell carcinoma highlights from ASCO GU 2025 include follow-up data from the CheckMate 9ER study, updated COSMIC-313 results, and promising early data on casdatifan, a new HIF-2 alpha inhibitor.

A study identified a link between sex hormones and renal cell carcinoma, suggesting potential new treatment strategies.

The following is a summary of “Metabolic syndrome and increased susceptibility to renal cell carcinoma – a meta-analysis,” ...

In an interview, Regina Barragan-Carrillo, MD, highlighted the ongoing global disparities in renal cell carcinoma clinical ...

A clinical trial demonstrates that personalised cancer vaccines effectively target mutations in high-risk kidney cancer, ...

Alan Tan, MD, discusses potential biomarkers that are being investigated to optimize treatment of patients with renal cell ...

A personalized vaccine demonstrated the potential to induce long-lasting immune response among people with advanced kidney ...

Metabolic Syndrome independently associated with increased susceptibility to renal cell carcinoma, finds study published in ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA was host to a session on the current state and future directions of ...

(UroToday.com) The 2025 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Annual Symposium held in San Francisco, CA between February 13–15, 2025 was host to a case-based session ...